Oncology Pipeline

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients.

VEGF Receptor-2 Antagonist

Ramucirumab

Adams RH and Alitalo K¹; Hicklin DJ and Ellis LM²

Target

Angiogenesis is a tightly regulated, multiple-step process, which results in the formation of new blood vessels from preexisting vasculature and is an important component in the development and progression of malignant disease. Signaling by vascular endothelial growth factor (VEGF) receptor-2 in endothelial cells plays a role in inducing normal and pathologic angiogenesis and is activated by binding of ligands VEGF-A, VEGF-C, and VEGF-D.^1-3

Molecule

Ramucirumab is a human IgG1 monoclonal antibody receptor antagonist that has been shown in vitro to bind to and block the activation of VEGF receptor-2 by preventing the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.^4,5

Clinical Development

Ramucirumab is being investigated in clinical trials in patients with non-small cell lung cancer or pediatric sarcoma.

References

Adams RH, Alitalo K. Nat Rev Mol Cell Biol. 2007;8(6):464-478.
Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23(5):1011-1027.
Olsson AK, et al. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
Lu D, et al. J Biol Chem. 2003;278(44):43496-43507.
Zhu Z, et al. Leukemia. 2003;17(3):604-611.

Need additional information or have a question:

Medical Science Liaison Request

The safety and efficacy of the agents under investigation have not been established. There is no guarantee that the agents will receive regulatory approval and become commercially available for the uses being investigated.

View All Trials For This Molecule

DISCOVER OTHER MOLECULES

BTK Inhibitor

Learn More

FGFR3 Inhibitor

Learn More

RET Inhibitor

Learn More